You are here

Novartis mulls options including spinoff, IPO for Alcon unit


NOVARTIS AG proposed buying back US$5 billion of shares and said it's considering separating its embattled eye-care division after projecting that sales this year at Europe's second-biggest drugmaker will likely be largely unchanged from 2016.

Earnings, excluding some...

Market voices on: